Godavari Biorefineries Q3 FY26: EBITDA up 14%, Profit Before Tax up 152%
Godavari Biorefineries reported a 14% YoY EBITDA growth to ₹45.1 crore and a 152% YoY increase in PBT to ₹21.4 crore for Q3 FY26. The bio-based chemical segment's EBITDA margin improved to 7.7%. The company secured a US patent for an anti-cancer molecule and its Jivana brand crossed ₹100 crore in revenue.
The announcement details strong financial results and strategic progress, including patent grants and business segment growth, which are significant but do not represent a major immediate shift in the company's core business or market position.
The company reported strong growth in EBITDA and Profit Before Tax, alongside margin expansion and strategic advancements, indicating positive financial and operational performance.
Godavari Biorefineries Limited reported a strong financial performance for the third quarter and nine months of FY26. In Q3 FY26, EBITDA grew by approximately 14% year-on-year to ₹45.1 crore, with EBITDA margins expanding by 97 basis points to 9.8%. Profit Before Tax (PBT) before exceptional items saw a significant increase of 152.2% to ₹21.4 crore, driven by operating leverage, an improved product mix, and disciplined cost management. Finance costs declined by 48% year-on-year.
For the nine-month period of FY26, total income stood at ₹1430.2 crore. EBITDA improved substantially to ₹47.2 crore from a marginal loss in the previous year, with margins strengthening to 3.3%. The bio-based chemical segment was a key contributor to profitability, with its EBITDA margin improving to 7.7% in Q3 FY26 from 4.5% in the corresponding quarter last year. The company also highlighted strategic advancements, including the grant of a US patent for an anti-cancer molecule and the incorporation of Sathgen Therapeutics LLC in the US to market its intellectual property.
Discussions during the investor call also touched upon managing feedstock availability and policy risks for the ethanol business, with the company diversifying its feedstock to include maize. The company is also progressing on its DME to CO2 technology initiative and its collaboration with Synthomer for bio-based alternatives. The consumer business, under the Jivana brand, crossed ₹100 crore in revenue for the first 9 months of FY26. The company reiterated its commitment to scaling high-margin businesses, capacity additions, and innovation.
What to do with a filing like this
Godavari Biorefineries Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Godavari Biorefineries Limited. Read the original for the full detail.